Hepatitis B virus reactivation
Conditions
Interventions
Discontinue NA administered for prevention of HBV reactivation in patients who have consented to clinical research in candidates from the following selection of research subjects.
Sponsors
Nagoya City University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who have undergone remission after anticancer therapy for solid tumors 2)Patients who have taken NA for more than 12 months to prevent reactivation of HBV. 3)Patients who started NA between January 2000 and March 2027 4)Patients who are 18 years of age or older at the time of initiation of NA administration 5)Patients who have obtained consent from the patient or the patient's surrogate
Exclusion criteria
Exclusion criteria: 1)Patients who do not meet any of the selection criteria 2)Patients with hematological diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients who required reintroduction of NA after discontinuation of NA administered for prevention of HBV reactivation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in HBV DNA, HBs antigen, and ALT after discontinuation of NA, and the presence of adverse events such as hepatitis. | — |
Countries
Japan
Contacts
Public ContactTakanori Suzuki
Nagoya City University Graduate School of Medical Sciences Department of Gastroenterology and Metabolism
Outcome results
None listed